The Korean Journal of Gastroenterology (대한소화기학회지)

The Korean Society of Gastroenterology (대한소화기학회)
권호 표지
DOI QR코드

DOI QR Code

Current Issues in Functional Dyspepsia

기능성 소화불량증의 최근 동향

  • Park, Jong Kyu (Department of Internal Medicine, University of Ulsan College of Medicine) ;
  • Huh, Kyu Chan (Department of Internal Medicine, Konyang University College of Medicine) ;
  • Shin, Cheol Min (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Lee, Hyuk (Department of Internal Medicine, Sungkyunkwan University School of Medicine) ;
  • Yoon, Young Hoon (Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Song, Kyung Ho (Department of Internal Medicine, Konyang University College of Medicine) ;
  • Min, Byung-Hoon (Department of Internal Medicine, Sungkyunkwan University School of Medicine) ;
  • Choi, Kee Don (Department of Internal Medicine, University of Ulsan College of Medicine) ;
  • Published : 2014.09.25
⟨ Previous Next ⟩

Abstract

Functional dyspepsia is one of the most common gastrointestinal disorders encountered in clinical practice. Functional dyspepsia is currently defined by Rome III criteria as the chronic dyspeptic symptoms (postprandial fullness, early satiety, epigastric pain or burning) in the absence of underling structural or metabolic disease that readily explain the symptoms. According to the Rome III consensus, functional dyspepsia can be subdivided into postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS). Although the Rome III criteria have been published more than 8 years ago, not much effort has been put into validating these criteria and direct scientific evidence supporting the validity of the subdividing functional dyspepsia into PDS and EPS are lacking. This article is intended to review the validity of the Rome III criteria on the subdivisions of functional dyspepsia, i.e. PDS and EPS. The impact of sleep disorder, Helicobacter pylori-associated dyspepsia, and the emerging drug therapies in functional dyspepsia will also be discussed in this article.

Keywords

References

  1. Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993;38:1569-1580. https://doi.org/10.1007/BF01303162
  2. El-Serag HB, Talley NJ. Health-related quality of life in functional dyspepsia. Aliment Pharmacol Ther 2003;18:387-393. https://doi.org/10.1046/j.1365-2036.2003.01706.x
  3. Nyren O, Lindberg G, Lindstrom E, Marke LA, Seensalu R. Economic costs of functional dyspepsia. Pharmacoeconomics 1992;1:312-324. https://doi.org/10.2165/00019053-199201050-00003
  4. Aro P, Talley NJ, Ronkainen J, et al. Anxiety is associated with uninvestigated and functional dyspepsia (Rome III criteria) in a Swedish population-based study. Gastroenterology 2009;137:94-100. https://doi.org/10.1053/j.gastro.2009.03.039
  5. Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006;130:1466-1479. https://doi.org/10.1053/j.gastro.2005.11.059
  6. Lee YY, Wahab N, Mustaffa N, et al. A Rome III survey of functional dyspepsia among the ethnic Malays in a primary care setting. BMC Gastroenterol 2013;13:84. https://doi.org/10.1186/1471-230X-13-84
  7. Ford AC, Bercik P, Morgan DG, Bolino C, Pintos-Sanchez MI, Moayyedi P. The Rome III criteria for the diagnosis of functional dyspepsia in secondary care are not superior to previous definitions. Gastroenterology 2014;146:932-940.e1. https://doi.org/10.1053/j.gastro.2014.01.014
  8. Goldsmith G, Levin JS. Effect of sleep quality on symptoms of irritable bowel syndrome. Dig Dis Sci 1993;38:1809-1814. https://doi.org/10.1007/BF01296103
  9. Kusano M, Kouzu T, Kawano T, Ohara S. Nationwide epidemiological study on gastroesophageal reflux disease and sleep disorders in the Japanese population. J Gastroenterol 2008;43:833-841. https://doi.org/10.1007/s00535-008-2235-0
  10. Futagami S, Yamawaki H, Izumi N, et al. Impact of sleep disorders in Japanese patients with functional dyspepsia (FD): nizatidine improves clinical symptoms, gastric emptying and sleep disorders in FD patients. J Gastroenterol Hepatol 2013;28:1314-1320. https://doi.org/10.1111/jgh.12236
  11. Talley NJ, Vakil NB, Moayyedi P. American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology 2005;129:1756-1780. https://doi.org/10.1053/j.gastro.2005.09.020
  12. Miwa H, Ghoshal UC, Fock KM, et al. Asian consensus report on functional dyspepsia. J Gastroenterol Hepatol 2012;27:626-641. https://doi.org/10.1111/j.1440-1746.2011.07037.x
  13. Suzuki H, Matsuzaki J, Hibi T. What is the difference between Helicobacter pylori-associated dyspepsia and functional dyspepsia? J Neurogastroenterol Motil 2011;17:124-130. https://doi.org/10.5056/jnm.2011.17.2.124
  14. Geeraerts B, Tack J. Functional dyspepsia: past, present, and future. J Gastroenterol 2008;43:251-255. https://doi.org/10.1007/s00535-008-2167-8
  15. Abid S, Siddiqui S, Jafri W. Discriminant value of Rome III questionnaire in dyspeptic patients. Saudi J Gastroenterol 2011;17:129-133. https://doi.org/10.4103/1319-3767.77244
  16. Vakil N, Talley N, van Zanten SV, et al; STARS I Study Group. Cost of detecting malignant lesions by endoscopy in 2741 primary care dyspeptic patients without alarm symptoms. Clin Gastroenterol Hepatol 2009;7:756-761. https://doi.org/10.1016/j.cgh.2009.03.031
  17. Kim ES, Lee BJ, Kim YS, Lee SI, Park H. Validation of Rome III criteria in the diagnosis of functional gastrointestinal disorders in Korean patients. Korean J Neurogastroenterol Motil 2008;14:39-44.
  18. Song KH, Jung HK, Min BH, et al. Development and validation of the Korean Rome III questionnaire for diagnosis of functional gastrointestinal disorders. J Neurogastroenterol Motil 2013;19:509-515. https://doi.org/10.5056/jnm.2013.19.4.509
  19. Talley NJ, Locke GR, Lahr BD, et al. Predictors of the placebo response in functional dyspepsia. Aliment Pharmacol Ther 2006;23:923-936. https://doi.org/10.1111/j.1365-2036.2006.02845.x
  20. Karamanolis G, Caenepeel P, Arts J, Tack J. Association of the predominant symptom with clinical characteristics and pathophysiological mechanisms in functional dyspepsia. Gastroenterology 2006;130:296-303. https://doi.org/10.1053/j.gastro.2005.10.019
  21. Laheij RJ, De Koning RW, Horrevorts AM, et al. Predominant symptom behavior in patients with persistent dyspepsia during treatment. J Clin Gastroenterol 2004;38:490-495. https://doi.org/10.1097/01.mcg.0000123164.86324.24
  22. Piessevaux H, De Winter B, Louis E, et al. Dyspeptic symptoms in the general population: a factor and cluster analysis of symptom groupings. Neurogastroenterol Motil 2009;21:378-388. https://doi.org/10.1111/j.1365-2982.2009.01262.x
  23. Castillo EJ, Camilleri M, Locke GR, et al. A community-based, controlled study of the epidemiology and pathophysiology of dyspepsia. Clin Gastroenterol Hepatol 2004;2:985-996. https://doi.org/10.1016/S1542-3565(04)00454-9
  24. Zagari RM, Law GR, Fuccio L, et al. Epidemiology of functional dyspepsia and subgroups in the Italian general population: an endoscopic study. Gastroenterology 2010;138:1302-1311. https://doi.org/10.1053/j.gastro.2009.12.057
  25. Min BH, Huh KC, Jung HK, et al; Functional Dyspepsia Study Group of Korean Society of Neurogastroenterology and Motility. Prevalence of uninvestigated dyspepsia and gastroesophageal reflux disease in Korea: a population-based study using the Rome III criteria. Dig Dis Sci 2014. [Epub ahead of print]
  26. Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. Gut 1999;45 (Suppl 2):II37-II42.
  27. Wang A, Liao X, Xiong L, et al. The clinical overlap between functional dyspepsia and irritable bowel syndrome based on Rome III criteria. BMC Gastroenterol 2008;8:43. https://doi.org/10.1186/1471-230X-8-43
  28. Park JM, Choi MG, Cho YK, et al. Functional gastrointestinal disorders diagnosed by Rome III questionnaire in Korea. J Neurogastroenterol Motil 2011;17:279-286. https://doi.org/10.5056/jnm.2011.17.3.279
  29. Haag S, Senf W, Tagay S, et al. Is there any association between disturbed gastrointestinal visceromotor and sensory function and impaired quality of life in functional dyspepsia? Neurogastroenterol Motil 2010;22:262-e79. https://doi.org/10.1111/j.1365-2982.2009.01415.x
  30. Shindo T, Futagami S, Hiratsuka T, et al. Comparison of gastric emptying and plasma ghrelin levels in patients with functional dyspepsia and non-erosive reflux disease. Digestion 2009;79:65-72. https://doi.org/10.1159/000205740
  31. Ahmed AB, Matre K, Hausken T, Gregersen H, Gilja OH. Rome III subgroups of functional dyspepsia exhibit different characteristics of antral contractions measured by strain rate imaging: a pilot study. Ultraschall Med 2012;33:E233-E240. https://doi.org/10.1055/s-0032-1313073
  32. Talley NJ, Walker MM, Aro P, et al. Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study. Clin Gastroenterol Hepatol 2007;5:1175-1183. https://doi.org/10.1016/j.cgh.2007.05.015
  33. Walker MM, Talley NJ, Prabhakar M, et al. Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther 2009;29:765-773. https://doi.org/10.1111/j.1365-2036.2009.03937.x
  34. Futagami S, Shindo T, Kawagoe T, et al. Migration of eosinophils and CCR2-/CD68-double positive cells into the duodenal mucosa of patients with postinfectious functional dyspepsia. Am J Gastroenterol 2010;105:1835-1842. https://doi.org/10.1038/ajg.2010.151
  35. Walker MM, Aggarwal KR, Shim LS, et al. Duodenal eosinophilia and early satiety in functional dyspepsia: confirmation of a positive association in an Australian cohort. J Gastroenterol Hepatol 2014;29:474-479. https://doi.org/10.1111/jgh.12419
  36. Oshima T, Nakajima S, Yokoyama T, et al. The G-protein beta3 subunit 825 TT genotype is associated with epigastric pain syndrome-like dyspepsia. BMC Med Genet 2010;11:13.
  37. Shimpuku M, Futagami S, Kawagoe T, et al. G-protein $\beta{3}$ subunit 825CC genotype is associated with postprandial distress syndrome with impaired gastric emptying and with the feeling of hunger in Japanese. Neurogastroenterol Motil 2011;23:1073-1080. https://doi.org/10.1111/j.1365-2982.2011.01781.x
  38. Park HY, Jahng JH, Lee YJ, Park HJ, Lee SI. Serotonin transporter gene and G-protein $\beta{3}$ C825T gene polymorphism in patients with functional dyspepsia and irritable bowel syndrome. Korean J Neurogastroenterol Motil 2009;15:58-64.
  39. Kim HG, Lee KJ, Lim SG, Jung JY, Cho SW. G-protein beta3 subunit C825T polymorphism in patients with overlap syndrome of functional dyspepsia and irritable bowel syndrome. J Neurogastroenterol Motil 2012;18:205-210. https://doi.org/10.5056/jnm.2012.18.2.205
  40. Park CS, Uhm JH. Polymorphisms of the serotonin transporter gene and G-protein $\beta{3}$ subunit gene in Korean children with irritable bowel syndrome and functional dyspepsia. Gut Liver 2012;6:223-228. https://doi.org/10.5009/gnl.2012.6.2.223
  41. Camilleri M, Stanghellini V. Current management strategies and emerging treatments for functional dyspepsia. Nat Rev Gastroenterol Hepatol 2013;10:187-194. https://doi.org/10.1038/nrgastro.2013.11
  42. Miwa H, Ghoshal UC, Gonlachanvit S, et al. Asian consensus report on functional dyspepsia. J Neurogastroenterol Motil 2012;18:150-168. https://doi.org/10.5056/jnm.2012.18.2.150
  43. Hsu YC, Liou JM, Yang TH, et al. Proton pump inhibitor versus prokinetic therapy in patients with functional dyspepsia: is therapeutic response predicted by Rome III subgroups? J Gastroenterol 2011;46:183-190. https://doi.org/10.1007/s00535-010-0334-1
  44. Xiao YL, Peng S, Tao J, et al. Prevalence and symptom pattern of pathologic esophageal acid reflux in patients with functional dyspepsia based on the Rome III criteria. Am J Gastroenterol 2010;105:2626-2631. https://doi.org/10.1038/ajg.2010.351
  45. Futagami S, Shimpuku M, Song JM, et al. Nizatidine improves clinical symptoms and gastric emptying in patients with functional dyspepsia accompanied by impaired gastric emptying. Digestion 2012;86:114-121. https://doi.org/10.1159/000339111
  46. Mazzoleni LE, Sander GB, Francesconi CF, et al. Helicobacter pylori eradication in functional dyspepsia: HEROES trial. Arch Intern Med 2011;171:1929-1936. https://doi.org/10.1001/archinternmed.2011.533
  47. Tack J, Masclee A, Heading R, et al. A dose-ranging, placebo-controlled, pilot trial of Acotiamide in patients with functional dyspepsia. Neurogastroenterol Motil 2009;21:272-280. https://doi.org/10.1111/j.1365-2982.2009.01261.x
  48. Matsueda K, Hongo M, Tack J, Saito Y, Kato H. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut 2012;61:821-828. https://doi.org/10.1136/gutjnl-2011-301454
  49. Henningsen P, Zimmermann T, Sattel H. Medically unexplained physical symptoms, anxiety, and depression: a meta-analytic review. Psychosom Med 2003;65:528-533. https://doi.org/10.1097/01.PSY.0000075977.90337.E7
  50. Shaker R, Castell DO, Schoenfeld PS, Spechler SJ. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol 2003;98:1487-1493. https://doi.org/10.1111/j.1572-0241.2003.07531.x
  51. Yi CH, Hu CT, Chen CL. Sleep dysfunction in patients with GERD: erosive versus nonerosive reflux disease. Am J Med Sci 2007;334:168-170. https://doi.org/10.1097/MAJ.0b013e318141f4a5
  52. Lacy BE, Everhart K, Crowell MD. Functional dyspepsia is associated with sleep disorders. Clin Gastroenterol Hepatol 2011;9:410-414. https://doi.org/10.1016/j.cgh.2011.02.010
  53. Yamawaki H, Futagami S, Shimpuku M, et al. Impact of sleep disorders, quality of life and gastric emptying in distinct subtypes of functional dyspepsia in Japan. J Neurogastroenterol Motil 2014;20:104-112. https://doi.org/10.5056/jnm.2014.20.1.104
  54. Lu CL, Chang SS, Wang SS, Chang FY, Lee SD. Silent peptic ulcer disease: frequency, factors leading to "silence," and implications regarding the pathogenesis of visceral symptoms. Gastrointest Endosc 2004;60:34-38. https://doi.org/10.1016/S0016-5107(04)01311-2
  55. Wang FW, Tu MS, Mar GY, et al. Prevalence and risk factors of asymptomatic peptic ulcer disease in Taiwan. World J Gastroenterol 2011;17:1199-1203. https://doi.org/10.3748/wjg.v17.i9.1199
  56. Azuma T. Helicobacter pylori CagA protein variation associated with gastric cancer in Asia. J Gastroenterol 2004;39:97-103. https://doi.org/10.1007/s00535-003-1279-4
  57. Yamaoka Y, Kato M, Asaka M. Geographic differences in gastric cancer incidence can be explained by differences between Helicobacter pylori strains. Intern Med 2008;47:1077-1083. https://doi.org/10.2169/internalmedicine.47.0975
  58. Liu Y, Vosmaer GD, Tytgat GN, Xiao SD, Ten Kate FJ. Gastrin (G) cells and somatostatin (D) cells in patients with dyspeptic symptoms: Helicobacter pylori associated and non-associated gastritis. J Clin Pathol 2005;58:927-931. https://doi.org/10.1136/jcp.2003.010710
  59. Pike BL, Porter CK, Sorrell TJ, Riddle MS. Acute gastroenteritis and the risk of functional dyspepsia: a systematic review and meta-analysis. Am J Gastroenterol 2013;108:1558-1563; quiz 1564. https://doi.org/10.1038/ajg.2013.147
  60. Gwee KA. Post-infectious irritable bowel syndrome, an inflammation-immunological model with relevance for other IBS and functional dyspepsia. J Neurogastroenterol Motil 2010;16:30-34. https://doi.org/10.5056/jnm.2010.16.1.30
  61. D'Elios MM, Andersen LP. Inflammation, immunity, and vaccines for Helicobacter pylori. Helicobacter 2009;14(Suppl 1):21-28. https://doi.org/10.1111/j.1523-5378.2009.00698.x
  62. Wren AM, Bloom SR. Gut hormones and appetite control. Gastroenterology 2007;132:2116-2130. https://doi.org/10.1053/j.gastro.2007.03.048
  63. Lee KJ, Cha DY, Cheon SJ, Yeo M, Cho SW. Plasma ghrelin levels and their relationship with gastric emptying in patients with dysmotility-like functional dyspepsia. Digestion 2009;80:58-63. https://doi.org/10.1159/000215389
  64. Kawashima J, Ohno S, Sakurada T, et al. Circulating acylated ghrelin level decreases in accordance with the extent of atrophic gastritis. J Gastroenterol 2009;44:1046-1054. https://doi.org/10.1007/s00535-009-0120-0
  65. Osawa H, Nakazato M, Date Y, et al. Impaired production of gastric ghrelin in chronic gastritis associated with Helicobacter pylori. J Clin Endocrinol Metab 2005;90:10-16. https://doi.org/10.1210/jc.2004-1330
  66. Takamori K, Mizuta Y, Takeshima F, et al. Relation among plasma ghrelin level, gastric emptying, and psychologic condition in patients with functional dyspepsia. J Clin Gastroenterol 2007;41:477-483. https://doi.org/10.1097/01.mcg.0000225614.94470.47
  67. Akamizu T, Iwakura H, Ariyasu H, et al; FD Clinical Study Team. Repeated administration of ghrelin to patients with functional dyspepsia: its effects on food intake and appetite. Eur J Endocrinol 2008;158:491-498. https://doi.org/10.1530/EJE-07-0768
  68. Saito Y, Suzuki H, Tsugawa H, et al. Dysfunctional gastric emptying with down-regulation of muscle-specific microRNAs in Helicobacter pylori-infected mice. Gastroenterology 2011;140:189-198. https://doi.org/10.1053/j.gastro.2010.08.044
  69. Suzuki H, Nishizawa T, Hibi T. Can Helicobacter pylori-associated dyspepsia be categorized as functional dyspepsia? J Gastroenterol Hepatol 2011;26(Suppl 3):42-45.
  70. Sugano K. Should we still subcategorize Helicobacter pylori-associated dyspepsia as functional disease? J Neurogastroenterol Motil 2011;17:366-371. https://doi.org/10.5056/jnm.2011.17.4.366
  71. Lee H, Jung HK, Huh KC; Functional Dyspepsia Study Group in the Korean Society of Neurogastroenterology and Motility. Current status of functional dyspepsia in Korea. Korean J Intern Med 2014;29:156-165. https://doi.org/10.3904/kjim.2014.29.2.156
  72. Jee SR, Jung HK, Min BH, et al; Korean Society of Neurogastroenterology and Motility. Guidelines for the treatment of functional dyspepsia. Korean J Gastroenterol 2011;57:67-81. https://doi.org/10.4166/kjg.2011.57.2.67
  73. Hallerback BI, Bommelaer G, Bredberg E, et al. Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study. Aliment Pharmacol Ther 2002;16:959-967. https://doi.org/10.1046/j.1365-2036.2002.01236.x
  74. Holtmann G, Talley NJ, Liebregts T, Adam B, Parow C. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med 2006;354:832-840. https://doi.org/10.1056/NEJMoa052639
  75. Talley NJ, Tack J, Ptak T, Gupta R, Giguere M. Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut 2008;57:740-746. https://doi.org/10.1136/gut.2007.132449
  76. Vakil N, Laine L, Talley NJ, et al. Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials. Am J Gastroenterol 2008;103:1906-1919.
  77. Arts J, Caenepeel P, Verbeke K, Tack J. Influence of erythromycin on gastric emptying and meal related symptoms in functional dyspepsia with delayed gastric emptying. Gut 2005;54:455-460. https://doi.org/10.1136/gut.2003.035279
  78. Tack J. Prokinetics and fundic relaxants in upper functional GI disorders. Curr Opin Pharmacol 2008;8:690-696. https://doi.org/10.1016/j.coph.2008.09.009
  79. McCallum RW, Lembo A, Esfandyari T, et al; TZP-102 Phase 2b Study Group. Phase 2b, randomized, double-blind 12-week studies of TZP-102, a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil 2013;25:e705-e717. https://doi.org/10.1111/nmo.12184
  80. Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998;115:1346-1352. https://doi.org/10.1016/S0016-5085(98)70012-5
  81. Tack J, Janssen P, Masaoka T, Farre R, Van Oudenhove L. Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. Clin Gastroenterol Hepatol 2012;10:1239-1245. https://doi.org/10.1016/j.cgh.2012.06.036
  82. Miwa H, Nagahara A, Tominaga K, et al. Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial. Am J Gastroenterol 2009;104:2779-2787. https://doi.org/10.1038/ajg.2009.427
  83. Kusunoki H, Haruma K, Manabe N, et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol Motil 2012;24:540-e251. https://doi.org/10.1111/j.1365-2982.2012.01897.x
  84. Matsueda K, Hongo M, Tack J, Aoki H, Saito Y, Kato H. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia: 100 mg t.i.d. is an optimal dosage. Neurogastroenterol Motil 2010;22:618-e173. https://doi.org/10.1111/j.1365-2982.2009.01449.x
  85. Hojo M, Miwa H, Yokoyama T, et al. Treatment of functional dyspepsia with antianxiety or antidepressive agents: systematic review. J Gastroenterol 2005;40:1036-1042. https://doi.org/10.1007/s00535-005-1687-8
  86. van Kerkhoven LA, Laheij RJ, Aparicio N, et al. Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2008;6:746-752; quiz 718. https://doi.org/10.1016/j.cgh.2008.02.051
  87. Braak B, Klooker TK, Wouters MM, Lei A, van den Wijngaard RM, Boeckxstaens GE. Randomised clinical trial: the effects of amitriptyline on drinking capacity and symptoms in patients with functional dyspepsia, a double-blind placebo-controlled study. Aliment Pharmacol Ther 2011;34:638-648. https://doi.org/10.1111/j.1365-2036.2011.04775.x
  88. Read NW, Abitbol JL, Bardhan KD, Whorwell PJ, Fraitag B. Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia. Gut 1997;41:664-668. https://doi.org/10.1136/gut.41.5.664
  89. Talley NJ, Choung RS, Camilleri M, Dierkhising RA, Zinsmeister AR. Asimadoline, a kappa-opioid agonist, and satiation in functional dyspepsia. Aliment Pharmacol Ther 2008;27:1122-1131. https://doi.org/10.1111/j.1365-2036.2008.03676.x

Cited by

  1. 하거허 상응부위 저주파 전침자극이 흰쥐의 장운동에 미치는 영향 vol.33, pp.1, 2016, https://doi.org/10.13045/acupunct.2016002
  2. 기능성 소화불량증에 사용된 침구치료방법에 대한 체계적 문헌고찰 vol.34, pp.1, 2017, https://doi.org/10.14406/acu.2016.030
  3. 건칠약침을 포함한 한방치료 후 호전된 소화불량 환자 5례에 대한 증례보고 vol.38, pp.5, 2014, https://doi.org/10.22246/jikm.2017.38.5.842
  4. Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia: A Randomized, Controlled Trial vol.12, pp.5, 2018, https://doi.org/10.5009/gnl17416
  5. 족삼리 전침 자극이 초음파로 측정된 위배출능에 미치는 영향 : 건강인 대상 예비연구 vol.39, pp.3, 2018, https://doi.org/10.22246/jikm.2018.39.3.426
  6. 한의 복진 정량화 연구 - 기능성 소화불량 환자의 복냉 진단을 중심으로 - vol.39, pp.4, 2014, https://doi.org/10.22246/jikm.2018.39.4.495
  7. 복부전방피부신경 영역의 자침으로 유발한 자율신경 및 위장관기능 변화에 대한 연구 vol.40, pp.1, 2014, https://doi.org/10.13048/jkm.19009
  8. 기능성소화불량과 만성 위축성 위염이 병발된 여성 환자에 대해 한방치료 경험 1례 vol.40, pp.4, 2014, https://doi.org/10.22246/jikm.2019.40.4.697
  9. Epidemiologic Properties of Functional Dyspepsia in Saudi Arabia vol.76, pp.6, 2014, https://doi.org/10.4166/kjg.2020.159
  10. The Effect of Proton Pump Inhibitor and Prokinetics Combination Therapy for Functional Dyspepsia vol.77, pp.4, 2021, https://doi.org/10.4166/kjg.2021.060
  11. 기능성소화불량 환자에서 나타나는 정신적 증상의 한약 치료 : 체계적 문헌고찰과 메타분석 vol.42, pp.4, 2021, https://doi.org/10.22246/jikm.2021.42.4.488